AAAAAA
Results:
1-18
|
Results: 18
Authors:
Emilien, G
Durlach, C
Aveaux, D
Maloteaux, JM
Citation: G. Emilien et al., Dopamine D-3 agonists, EXPERT OP T, 11(11), 2001, pp. 1713-1728
Authors:
Robinet, EA
Geurts, M
Maloteaux, JM
Pauwels, PJ
Citation: Ea. Robinet et al., Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA, NEUROSCI L, 307(1), 2001, pp. 45-48
Authors:
Emilien, G
Misteli, C
Aveaux, D
Maloteaux, JM
Citation: G. Emilien et al., Life after sequencing, TRENDS BIOT, 19(7), 2001, pp. 246-246
Authors:
Page, G
Peeters, M
Najimi, M
Maloteaux, JM
Hermans, E
Citation: G. Page et al., Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes, J NEUROCHEM, 76(5), 2001, pp. 1282-1290
Authors:
Emilien, G
Ponchon, M
Caldas, C
Isacson, O
Maloteaux, JM
Citation: G. Emilien et al., Impact of genomics on drug discovery and clinical medicine, QJM-MON J A, 93(7), 2000, pp. 391-423
Authors:
Emilien, G
van Meurs, W
Maloteaux, JM
Citation: G. Emilien et al., The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment, PHARM THERA, 88(1), 2000, pp. 33-58
Authors:
Emilien, G
Maloteaux, JM
Penasse, C
Goodeve, A
Casimir, C
Citation: G. Emilien et al., Haemophilias: advances towards genetic engineering replacement therapy, CLIN LAB H, 22(6), 2000, pp. 313-323
Authors:
Noel, F
Geurts, M
Maloteaux, JM
Citation: F. Noel et al., Selective destruction of nigrostriatal dopaminergic neurons does not alter[H-3]-ryanodine binding in rat striatum, BRAZ J MED, 33(2), 2000, pp. 237-240
Authors:
Page, G
Peeters, M
Maloteaux, JM
Hermans, E
Citation: G. Page et al., Increased dopamine uptake in striatal synaptosomes after treatment of ratswith amantadine, EUR J PHARM, 403(1-2), 2000, pp. 75-80
Authors:
Emilien, G
Beyreuther, K
Masters, CL
Maloteaux, JM
Citation: G. Emilien et al., Prospects for pharmacological intervention in Alzheimer disease, ARCH NEUROL, 57(4), 2000, pp. 454-459
Authors:
Emilien, G
Maloteaux, JM
Beyreuther, K
Masters, CL
Citation: G. Emilien et al., Alzheimer disease - Mouse models pave the way for therapeutic opportunities, ARCH NEUROL, 57(2), 2000, pp. 176-181
Authors:
Emilien, G
Maloteaux, JM
Citation: G. Emilien et Jm. Maloteaux, Circadian system and sleep anomaly in depression, IRIS J PS M, 16(1), 1999, pp. 18-23
Authors:
Emilien, G
Maloteaux, JM
Geurts, M
Hoogenberg, K
Cragg, S
Citation: G. Emilien et al., Dopamine receptors - physiological understanding to therapeutic intervention potential, PHARM THERA, 84(2), 1999, pp. 133-156
Authors:
Emilien, G
Maloteaux, JM
Ponchon, M
Citation: G. Emilien et al., Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment, PHARM THERA, 81(1), 1999, pp. 37-51
Authors:
Geurts, M
Hermans, E
Maloteaux, JM
Citation: M. Geurts et al., Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [S-35]GTP gamma S binding, LIFE SCI, 65(16), 1999, pp. 1633-1645
Authors:
Geurts, M
Hermans, E
Maloteaux, JM
Citation: M. Geurts et al., Enhanced striatal dopamine D-2 receptor-induced [S-35]GTP gamma S binding after haloperidol treatment, EUR J PHARM, 382(2), 1999, pp. 119-127
Dopamine receptor-modulated [S-35]GTP gamma S binding in striatum of 6-hydroxydopamine-lesioned rats
Authors:
Geurts, M
Hermans, E
Cumps, J
Maloteaux, JM
Citation: M. Geurts et al., Dopamine receptor-modulated [S-35]GTP gamma S binding in striatum of 6-hydroxydopamine-lesioned rats, BRAIN RES, 841(1-2), 1999, pp. 135-142
Authors:
Hantson, P
Leonard, F
Maloteaux, JM
Mahieu, P
Citation: P. Hantson et al., How epileptogenic are the recent antibiotics?, ACT CLIN B, 54(2), 1999, pp. 80-87
Risultati:
1-18
|